Biocon strengthens on plan to launch psoriasis drug in July this year

29 Apr 2013 Evaluate

Biocon is currently trading at Rs 280.70, up by 2.20 points or 0.79% from its previous closing of Rs 278.50 on the BSE.

The scrip opened at Rs 279.90 and has touched a high and low of Rs 281.85 and Rs 279.90 respectively. So far 9728 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 321.50 on 16-Nov-2012 and a 52 week low of Rs 208.10 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs 290.70 and Rs 275.50 respectively. The current market cap of the company is Rs 5570.00 crore.

The promoters holding in the company stood at 60.96% while Institutions and Non-Institutions held 17.04% and 21.99% respectively.

Biocon, Asia's premier biotechnology company, plans to launch its novel biologic drug Itolizumab branded as ‘Alzumab’ to be used for the treatment of chronic plaque psoriasis in the country. The biotechnology major is planning to launch it in month of July this year. The drug will be manufactured at the company’s biopharma manufacturing facility at Biocon Park in Bangalore.

In January 2013, the company received marketing authorization for Itolizumab from the Drugs Controller General of India. The company has also completed a pre-IND (Investigational New Drug) meeting for Itolizumab with the US Food and Drug Administration as it plans for a global clinical development of the new medicine. This is company’s second novel biologic developed in India. BioMab EGFR, an anti-cancer monoclonal antibody being the first.

Psoriasis is an inflammatory auto-immune skin disease that follows a typical relapsing and remitting course with the disease affecting 2-3% of the total population in the country. The global market for psoriasis treatments is estimated to cross $8 billion by 2016.

Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

390.20 -0.05 (-0.01%)
30-Dec-2025 11:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.15
Dr. Reddys Lab 1268.00
Cipla 1489.20
Zydus Lifesciences 901.60
Lupin 2073.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×